Blood Glucose Control

HbA1c testing determines diabetes and prediabetes in patients who are not yet diagnosed

Does HbA1c variability predict retinopathy, nephropathy?

Guest Post by David Kliff, Diabetic Investor
The FDA approved Dexcom’s request for a non-adjunctive claim this week. It looks like a bad situation for conventional glucose monitors, and believe it or not is about to get worse. Here’s why.

Male, 26 years of age, type 2 diabetes, obesity, hyperlipidemia, hypertension. Strong family history of type 2 diabetes with complications. Has been a patient since diagnosed 2 years ago. Has met with dietitian. Hasn’t made dietary changes, increased activity, or taken meds prescribed to lower his glucose. A1C 9.2% and rising every 3 months. He would also miss many of his appointments. Stated, “Nothing is going to bother me. Maybe it did my family, but that was a different time and it’s not going to happen to me. I’m going to go on enjoying my life.”

In part 1 of this Exclusive Interview, Kimberly Ward explains the goal and use of the Accu-Chek Connect System.

System shows significant improvement in HbA1c compared to current best therapy available.

16-year-old male, type 1 diabetes since 2 years of age, pump therapy. Eats about the same thing daily. Post prandials vary widely. When corrects for highs, gets low.

Diabetes screening should be protocol test in all health centers, health fairs to prevent undiagnosed diabetes and avoid later complications.

Male, 32 years of age. Works erratic hours. Recently came up with a plan of how to remember to take his meds. He started setting up and taking his pill box with him. He has succeeded at taking his medications and taking them on time…all except his injectable medications.

Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.